Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has a stable fundamental performance, with progress in innovation and internationalization accelerating [1] - In 2025, the company reported revenue of 12.02 billion yuan (up 1.76% year-on-year) and a net profit attributable to shareholders of 2.023 billion yuan (down 1.84% year-on-year) [3][4] - The company maintains a gross margin of 65.90% (up 0.45 percentage points) and a net margin of 20.06% (up 0.55 percentage points) [3] - The company is optimistic about its innovation and internationalization strategies, although the promotion of new products like IL-17A/F will take time, leading to a downward revision of profit forecasts for 2026-2028 [4] Financial Performance - In 2025, the revenue breakdown by business segment includes: - Chemical preparations: 6.222 billion yuan (up 1.67%) - Traditional Chinese medicine: 1.674 billion yuan (up 18.81%) - Biopharmaceuticals: 201 million yuan (up 17.5%) [4] - The company expects net profits for 2026, 2027, and 2028 to be 2.125 billion yuan, 2.394 billion yuan, and 2.751 billion yuan respectively, with corresponding EPS of 2.39 yuan, 2.70 yuan, and 3.10 yuan [4] - The current stock price corresponds to a P/E ratio of 13.9, 12.4, and 10.8 for the years 2026, 2027, and 2028 respectively [4] Research and Development Progress - The company is advancing its differentiated innovation pipeline, with key products such as Aripiprazole microspheres approved for market in May 2025 and IL-17A/F expected to enter commercialization in 2026 [5] - The company is also expanding its local presence in Southeast Asia, having initiated the acquisition of Vietnamese listed company Imexpharm to leverage local resources for the development and commercialization of innovative and high-end generic drugs [5]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Insights - The company has a stable fundamental performance, with progress in innovation and internationalization accelerating [1] - In 2025, the company reported a revenue of 12.02 billion yuan (up 1.76% year-on-year) and a net profit attributable to shareholders of 2.023 billion yuan (down 1.84% year-on-year) [3][4] - The company is focusing on differentiated innovation and has a robust product pipeline, including the approval of Aripiprazole microspheres and advancements in IL-17A/F products [5] Financial Performance - In 2025, the company's gross margin was 65.90% (up 0.45 percentage points), and the net profit margin was 20.06% (up 0.55 percentage points) [3] - The sales expense ratio increased to 29.79% (up 2.24 percentage points), while the management expense ratio decreased to 4.98% (down 0.21 percentage points) [3] - The company expects net profits for 2026, 2027, and 2028 to be 2.125 billion yuan, 2.394 billion yuan, and 2.751 billion yuan respectively, with corresponding EPS of 2.39 yuan, 2.70 yuan, and 3.10 yuan [4][5] Business Segmentation - In 2025, the chemical preparations segment generated 6.222 billion yuan (up 1.67%), with notable contributions from various product categories [4] - The traditional Chinese medicine segment achieved 1.674 billion yuan (up 18.81%), while the biopharmaceutical segment reached 201 million yuan (up 17.5%) [4] - The company is enhancing its local and regional strategies, including the acquisition of a Vietnamese pharmaceutical company to leverage local resources [5]

Core Viewpoint - Lijun Group (000513) focuses on the development of microsphere technology, particularly in the areas of GnRH-α and mental health products, with significant advancements in long-acting formulations and international market expansion [1] Group 1: Product Development - The core product, Leuprolide microsphere (one-month release), is the first GnRH-α long-acting formulation approved by the FDA based on individual drug guidelines [1] - The injectable Triptorelin microsphere has received approval for prostate cancer and is expected to be approved for endometriosis in 2024, with ongoing Phase III clinical trials for central precocious puberty [1] - A three-month release Leuprolide microsphere application has been submitted, with expected approval in 2026 [1] - The company is also developing a microsphere formulation of Ganirelix, which currently has no market presence globally [1] Group 2: Mental Health Product Line - The company has launched an injectable Aripiprazole microsphere, which offers the longest dosing interval (once a month) for schizophrenia treatment globally [1] - Additional products like Brexpiprazole microsphere are in development to strengthen the long-acting product line for mental health [1] Group 3: Market Expansion in Vietnam - The acquisition of Imexpharm in Vietnam is under approval, with the company showing over 20% growth in revenue, profit, and EBITDA in the third quarter [1] - Imexpharm has the largest EU-GMP product line in Vietnam, and both companies are planning product and process transfers to leverage Imexpharm's established market channels and EU-GMP certification for expanding innovative drug products overseas [1]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company achieved a revenue of 6.272 billion yuan in H1 2025, a slight decrease of 0.17% year-on-year, while the net profit attributable to the parent company was 1.281 billion yuan, reflecting a growth of 9.40% year-on-year [4] - The company maintains a strong gross margin of 66.02% and a net profit margin of 24.73%, with significant improvements in net profit margin by 3.17 percentage points year-on-year [4] - The company is expected to continue its differentiated innovation strategy, with projected net profits of 2.276 billion yuan, 2.521 billion yuan, and 2.801 billion yuan for the years 2025, 2026, and 2027 respectively, leading to an EPS of 2.52 yuan, 2.79 yuan, and 3.10 yuan per share [4] Financial Performance Summary - In H1 2025, the company's sales expenses ratio was 27.69%, management expenses ratio was 4.77%, and R&D expenses ratio was 6.89% [4] - The company’s chemical preparations generated 3.270 billion yuan in revenue, with notable performance in digestive products (1.351 billion yuan, +3.87%) and psychiatric products (0.317 billion yuan, +6.89%) [5] - The company’s diversified product matrix is advancing rapidly, with several innovative drugs in the pipeline, including a long-acting formulation of Aripiprazole and a small nucleic acid drug targeting uric acid production [6] Financial Projections - The company is projected to have a revenue of 12.247 billion yuan in 2025, with a year-on-year growth of 3.7% [7] - The projected P/E ratios for 2025, 2026, and 2027 are 16.4, 14.8, and 13.3 respectively, indicating a favorable valuation trend [7]

R&D Progress and Key Projects - LZM012, targeting IL-17A/F, is the first IL-17A/F inhibitor to complete Phase III clinical trials in China, showing a PASI100 response rate of 49.5%, outperforming the control group at 40.2% [6][7] - LZHN2408, for gout with hyperuricemia, has received clinical approval and is currently in Phase I trials, demonstrating safety and efficacy in preclinical studies [3][8] - H001, an anticoagulant for post-surgical venous thromboembolism, has completed patient enrollment in Phase II trials, showing comparable efficacy to enoxaparin with lower bleeding risks [3][4] New Drug Development - NS-041, a new generation KCNQ2/3 activator for epilepsy, has completed Phase I trials and is set to enroll over 280 patients in Phase II, with no similar drugs currently on the market [4] - SG1001, targeting invasive fungal infections, has completed Phase I trials and is expected to address drug resistance issues [5] - JP-1366, a P-CAB product, has completed Phase III trials and will soon submit for market approval, filling a gap in the domestic P-CAB injection market [5] Strategic Initiatives - The company plans to introduce 6 new drug projects in 2024, with 5 being innovative drugs, focusing on consolidating its leading position in gastrointestinal and neurological fields [9][10] - The acquisition of Vietnam's IMP Company aims to enhance market presence in Southeast Asia, leveraging local production capabilities and distribution networks [11] Clinical Data and Market Potential - LZM012's Phase III data indicates a low adverse reaction rate compared to the control drug, with ongoing evaluations for additional indications and potential overseas licensing [7][10] - The small RNA technology platform is being developed to enhance drug delivery systems, with a focus on the gout project as a leading initiative [8] Efficiency Improvements - The company has reformed its R&D system to improve efficiency through strategic project management and resource allocation, focusing on high-quality advancements in key therapeutic areas [11]

Investment Rating - The investment rating for the company is "Buy" (maintained) [1] Core Views - The company has achieved superior efficacy in the IL-17A/F head-to-head III phase clinical trial for psoriasis, demonstrating a PASI 100 response rate of 49.5% compared to 40.2% for the control group [3] - The company is expected to maintain a strong growth trajectory with projected net profits of 2.276 billion, 2.521 billion, and 2.801 billion yuan for 2025-2027, respectively, with corresponding EPS of 2.52, 2.79, and 3.10 yuan per share [3][4] - The current price-to-earnings (PE) ratios are projected to be 17.4, 15.7, and 14.2 for the years 2025, 2026, and 2027, indicating a favorable valuation [3] Financial Summary - The company reported a revenue of 12.430 billion yuan in 2023, with a slight decline expected in 2024 to 11.812 billion yuan, followed by a recovery to 12.247 billion yuan in 2025 [6] - The gross margin is projected to be 64.1% in 2023, slightly decreasing to 62.9% in 2025, while the net profit margin is expected to stabilize around 19.5% for 2025 [6][8] - Return on equity (ROE) is forecasted to be 14.7% in 2025, with a gradual increase to 15.0% by 2027 [6][8]